

Podcast Show Notes

Listen, Learn, and Earn CE Hours with this podcast course. Available on [Apple](#), [Spotify](#), and other podcast apps.

COVID Update

After several years of the SARS-CoV-2 or COVID-19 pandemic, where do we stand now? Many may be curious about the most recent variants, herd immunity, latest testing advice, and current treatment options. Are we nearing a possible end of the pandemic phase of COVID-19? Tune in for a conversation between an infectious disease expert physician and a nurse to discuss “Where are we now?” in regard to coronavirus disease. They also discuss how important interprofessional and interpersonal communication is for the healthcare team to support each other and provide quality care.

This CE course is relevant to medicine and nursing.

At Colibri Healthcare, we developed this educational content with a genuine approach to bringing attention to mental health and other serious situations from a healthcare professional's perspective. This podcast contains content that may be unsettling for some listeners. The episodes may discuss death, suicide, depression, and other sensitive topics. We do our best to discuss sensitive topics such as these with discretion and sincerity. Because of the sensitive topic being discussed, we recommend this podcast for adults only.

Content warnings: Mentions of death and suicide

Episode 1 – An Update on Where We are After 3 Years of SARS-CoV-2 and COVID-19

In this episode, we provide a basic update and brief overview of interventions for combatting COVID-19 such as testing, masking, ventilation, vaccines/boosters, and medications. Dr. Griffin discusses concepts to consider for analyzing our responses to newer variants and how the virus is transmitted. In addition, he explains some interesting aspects regarding cell-mediated immunity and how this may impact COVID in the future.

Guest

Daniel Griffin, PhD, MD

- Board-certified in internal medicine and infectious disease
- Expertise in global health, tropical medicine, parasitology, and virology

- International speaker for organizations such as the University of Glasgow, the University of Minnesota, the Peace Corps, the Foundation for International Medical Relief for Children, Floating Doctors, and Remote Care Education
- Podcast co-host of “*This Week in Virology*” and “*This Week in Parasitism*”
- Co-author, *Parasitic Diseases*, 7th edition

Host

Leana McGuire, BS, RN

Leana McGuire has extensive experience with leadership development and executive coaching, and a background in content development, visual performance, speaking, and podcast hosting.

Content Reviewer

Maria Morales, MSN, RN, CLNC

Maria Morales is a nurse planner for Colibri Healthcare and a certified legal nurse consultant. She is a quality-focused, results-driven nursing education professional. As a continuing education leader with nurse executive experience in developing interprofessional educational programs, she supports healthcare workers with educational activities to help increase communication within the healthcare team.

References

- Abaluck, J., Kwong, L. H., Styczynski, A., Haque, A., Kabir, M. A., Bates-Jefferys, E., Crawford, E., Benjamin-Chung, J., Raihan, S., Rahman, S., Benhachmi, S., Binte, N. Z., Winch, P. J., Hossain, M., Reza, H. M., Jaber, A. A., Momen, S. G., Rahman, A., Banti, F. L., ... & Mobarak, A. M. (2022). Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh. *Science*, 375(6577), eabi9069.
<https://doi.org/10.1126/science.abi9069>
- Arbel, R., Sagy, Y. W., Hoshen, M., Battat, E., Lavie, G., Sergienko, R., Friger, M., Waxman, J. G., Dagan, N., Balicer, R., Ben-Shlomo, Y., Peretz, A., Yaron, S., Serby, D., Hammerman, A., & Netzer, D. (2022). Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge. *New England Journal of Medicine*, 387, 790-8.
<https://doi.org/10.1056/NEJMoa2204919>
- Brodin, R., van der Werff, S. D., Hedberg, P., Färnert, A., Naulé, P., Bergman, P., & Requena-Méndez, A. (2022). The association between pre-exposure to glucocorticoids and other immunosuppressant drugs with severe COVID-19 outcomes. *Clinical Microbiology and Infection*, 28(11), 1477-85.
<https://doi.org/10.1016/j.cmi.2022.05.014>
- Butler, C. C., Yu, L. M., Dorward, J., Gbinigie, O., Hayward, G., Saville, B. R., Van Hecke, O., Berry, N., Detry, M. A., Saunders, C., Fitzgerald, M., Harris, V., Djukanovic, R., Gadola, S., Kirkpatrick, J., de Lusignan, S., Ogburn, E., Evans, P. H., Thomas, N. P. B., Patel, M. G., Richard Hobbs, F. D., & PRINCIPLE Trial Collaborative Group. (2021). Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet: Respiratory Medicine*, 9(9), 1010-20. [https://doi.org/10.1016/S2213-2600\(21\)00310-6](https://doi.org/10.1016/S2213-2600(21)00310-6)
- Centers for Disease Control and Prevention. (2021). *Ventilation in buildings*. CDC.
<https://www.cdc.gov/coronavirus/2019-ncov/community/ventilation.html>
- Centers for Disease Control and Prevention. (2022). *Improving ventilation in your home*. CDC.
<https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/improving-ventilation-home.html>

- Centers for Disease Control and Prevention. (2022). *Isolation and precautions for people with COVID-19*. CDC. https://www.cdc.gov/coronavirus/2019-ncov/your-health/isolation.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fyour-health%2Fquarantine-isolation.html
- Centers for Disease Control and Prevention. (2023). *COVID-19 data review: Update on COVID-19-related mortality*. CDC. <https://www.cdc.gov/coronavirus/2019-ncov/science/data-review/index.html>
- Centers for Disease Control and Prevention. (2023). *COVID data tracker: Variant proportions*. CDC. <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>
- Chou, R., Dana, T., & Jungbauer, R. (2022). Update alert 8: Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings. *Annals of Internal Medicine*, 175(9), W108–9. <https://doi.org/10.7326/L22-0272>
- Cowger, T. L., Murray, E. J., Clarke, J., Bassett, M. T., Ojikutu, B. O., Sánchez, S. M., Linos, N., & Hall, K. T. (2022). Lifting universal masking in schools - Covid-19 incidence among students and staff. *New England Journal of Medicine*, 387(21), 1935–46. <https://doi.org/10.1056/NEJMoa2211029>
- Cuker, A., Tseng, E. K., Nieuwlaat, R., Angchaisuksiri, P., Blair, C., Dane, K., Davila, J., DeSancho, M. T., Diuguid, D., Griffin, D. O., Kahn, S. R., Klok, F. A., Lee, A. I., Neumann, I., Pai, A., Righini, M., Sanfilippo, K. M., Siegal, D., Skara, M., ... & Schünemann, H. J. (2021). American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. *Blood Advances*, 5(20), 3951–9. <https://doi.org/10.1182/bloodadvances.2021005493>
- Department of Health and Human Services. (n.d.). *Your COVID-19 toolkit*. <https://www.covid.gov/>
- De Vito, A., Colpani, A., Bitti, A., Zauli, B., Meloni, M. C., Fois, M., Denti, L., Bacciu, S., Marcia, C., Maida, I., Babudieri, S., & Madeddu, G. (2022). Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience. *Journal of Medical Virology*, 94(11), 5582–8. <https://doi.org/10.1002/jmv.28011>
- Eli Lilly and Company. (2022). *Fact sheet for healthcare providers: Emergency use authorization for bebtelovimab*. <https://www.fda.gov/media/156152/download>
- Epling, B. P., Rocco, J. M., Boswell, K. L., Laidlaw, E., Galindo, F., Kellogg, A., Das, S., Roder, A., Ghedin, E., Kreitman, A., Dewar, R. L., Kelly, S. E. M., Kalish, H., Rehman, T., Highbarger, J., Rupert, A., Kocher, G., Holbrook, M. R., Lisco, A., Manion, M., Koup, R. A., & Sereti, I. (2022). Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following nirmatrelvir/ritonavir treatment. *Clinical Infectious Diseases*, ciac663. <https://doi.org/10.1093/cid/ciac663>
- Gilead Sciences, Inc. (n.d.). *Veklury® remdesivir*. https://www.vekluryhcp.com/?utm_id=iw_sa_11453738585_111635246813&utm_medium=cpc&utm_term=medicine+remdesivir&gclid=CjwKCAjwj42UBhAAEiwACIhADocodyE-OQCnF5PXs6x5nuFnH230Tc-4V3iFulmtEoxHgYAY1Tr7hhoCTOoQAvD_BwE&gclsrc=aw.dshttps://files.constantcontact.com/17b067e5501/04046d2f-51dc-490f-89e1-edb5c535eeb6.pdf?rdr=true
- Gottlieb, R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., Hidalgo, A., Sachdeva, Y., Mittal, S., Osiyemi, O., Skarbinski, J., Juneja, K., Hyland, R. H., Osinusi, A., Chen, S., ... & GS-US-540-9012 (PINETREE) Investigators. (2022). Early remdesivir to prevent progression to severe

- Covid-19 in outpatients. *New England Journal of Medicine*, 386(4), 305–15.
<https://doi.org/10.1056/NEJMoa2116846>
- Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M. (2022). Oral nirmatrelvir for high-risk, Nonhospitalized adults with Covid-19. *New England Journal of Medicine*, 386, 1397-1408.
<https://doi.org/10.1056/NEJMoa2118542>
- Hinks, T. S. C., Cureton, L., Knight, R., Wang, A., Cane, J. L., Barber, V. S., Black, J., Dutton, S. J., Melhorn, J., Jabeen, M., Moss, P., Garlapati, R., Baron, T., Johnson, G., Cattle, F., Clarke, D., Elkhodair, S., Underwood, J., Lasserson, D., ...Richards, D. (2021). Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): An open-label, randomised trial. *Lancet: Respiratory Medicine*, 9(10), 1130–40.
[https://doi.org/10.1016/S2213-2600\(21\)00263-0](https://doi.org/10.1016/S2213-2600(21)00263-0)
- Infectious Diseases Society of America. (2023). *IDSA guidelines on the treatment and management of patients with COVID-19*. <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>
- Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., Du, J., Pedley, A., Assaid, C., Strizki, J., Grobler, J. A., Shamsuddin, H. H., Tipping, R., Wan, H., Paschke, A., ... & MOVE-OUT Study Group. (2022). Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. *New England Journal of Medicine*, 386(6), 509–20.
<https://doi.org/10.1056/NEJMoa2116044>
- Klaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., & Menzies, N. A. (2022). *Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022*. MedRxiv.
<https://doi.org/10.1101/2022.11.19.22282525>
- Link-Gelles, R., Ciesla, A. A., Fleming-Dutra, K. E., Smith, Z. R., Britton, A., Wiegand, R. E., Miller, J. D., Accorsi, E. K., Schrag, S. J., Verani, J. R., Shang, N., Derado, G., & Pilishvili, T. (2022). Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection — Increasing community access to testing program, United States, September–November 2022. *MMWR Morbidity and Mortality Weekly Report*, 71, 1526–30. <http://dx.doi.org/10.15585/mmwr.mm7148e1>
- Møller Kirsebom, F. C., Andrews, N., Stowe, J., Groves, N., Chand, M., Ramsay, M., & Bernal, J. L. (2022). Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England. *Lancet: Regional Health: Europe*, 23, 100537. <https://doi.org/10.1016/j.lanepe.2022.100537>
- National Institutes of Health. (2023). *Coronavirus disease 2019 (COVID-19) treatment guidelines*.
<https://www.covid19treatmentguidelines.nih.gov/>
- Oldenburg, C. E., Pinsky, B. A., Brogdon, J., Chen, C., Ruder, K., Zhong, L., Nyatigo, F., Cook, C. A., Hinterwirth, A., Lebas, E., Redd, T., Porco, T. C., Lietman, T. M., Arnold, B. F., & Doan, T. (2021). Effect of oral azithromycin vs placebo on COVID-19 symptoms in outpatients with SARS-CoV-2 infection: A randomized clinical trial. *JAMA*, 326(6), 490–8. <https://doi.org/10.1001/jama.2021.11517>
- Pfizer. (2023). *Fact sheet for healthcare providers: Emergency use authorization for Paxlovid™*.
<https://www.fda.gov/media/155050/download>
- PRINCIPLE Trial Collaborative Group. (2021). Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): A randomised, controlled,

open-label, adaptive platform trial. *Lancet*, 397(10279), 1063–74. [https://doi.org/10.1016/S0140-6736\(21\)00461-X](https://doi.org/10.1016/S0140-6736(21)00461-X)

Rajme-López, S., Martínez-Guerra, B. A., Zalapa-Soto, J., Román-Montes, C. M., Tamez-Torres, K. M., González-Lara, M. F., Hernández-Giloslul, T., Kershenobich-Stalnikowitz, D., Sifuentes-Osornio, J., Ponce-de-León, A., & Ruíz-Palacios, G. M. (2022). Early outpatient treatment with remdesivir in patients at high risk for severe COVID-19: A prospective cohort study. *Open Forum Infectious Diseases*, 9(10), ofac502. <https://doi.org/10.1093/ofid/ofac502>

Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan, C., Chappell, L. C., Faust, S. N., Jaki, T., ... & Landray, M. J. (2021). Dexamethasone in hospitalized patients with Covid-19. *New England Journal of Medicine*, 384(8), 693–704. <https://doi.org/10.1056/NEJMoa2021436>

Sahu, A. K., Mathew, R., Bhat, R., Malhotra, C., Nayer, J., Aggarwal, P., & Galwankar, S. (2021). Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and meta-analysis. *QJM: An International Journal of Medicine*, 114(7), 455–63. <https://doi.org/10.1093/qjmed/hcab212>

Shah, M. M., Joyce, B., Plumb, I. D., Sahakian, S., Feldstein, L. R., Barkley, E., Paccione, M., Deckert, J., Sandmann, D., Gerhar, J. L., & Briggs Hagan, M. (2022). Paxlovid associated with decreased hospitalization rate among adults with COVID-19 — United States, April–September 2022. *MMWR Morbidity and Mortality Weekly Report*, 71(48), 1531–7. <http://dx.doi.org/10.15585/mmwr.mm7148e2>

Solera, J. T., Árbol, B. G., Bahinskaya, I., Marks, N., Humar, A., & Kumar, D. (2023). Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave. *American Journal of Transplantation*, 23(1), 78–83. <https://doi.org/10.1111/ajt.17199>

Trinkl, J., Bartelt, K., Joyce, B., Sahakian, S., Sandberg, N., Allen, S., Gerhart, J., Barkley, E., & Sweet C. (2022). Paxlovid significantly reduces COVID-19 hospitalizations and deaths. *Epic Research*. <https://epicresearch.org/articles/paxlovid-significantly-reduces-covid-19-hospitalizations-and-deaths>

World Health Organization. (2023). *Therapeutics and COVID-19: Living guideline*. <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.1>

Resources

Infectious Diseases Society of America. (2022). *Management of drug interactions with nirmatrelvir/ritonavir (paxlovid®): Resource for clinicians*. <https://www.idsociety.org/paxlovid>

University of Liverpool. (n.d.). *COVID-19 drug interactions*. <https://www.covid19-druginteractions.org/checker>

Episode 2 – Interprofessional Communication and Interpersonal Relationships in Healthcare Related to COVID-19 and Beyond

This episode continues the conversation about COVID-19 in light of how healthcare team members can communicate better interprofessionally and interpersonally to provide improved care to patients and enhanced support for each other. Dr. Griffin also discusses herd immunity with regard to coronavirus, living in a sea of microorganisms where viruses mutate, and the seriousness of avoiding inappropriate use of antibiotics for viral infections.

Guest

Daniel Griffin, PhD, MD

- Board-certified in internal medicine and infectious disease
- Expertise in global health, tropical medicine, parasitology, and virology
- International speaker for organizations such as the University of Glasgow, the University of Minnesota, the Peace Corps, the Foundation for International Medical Relief for Children, Floating Doctors, and Remote Care Education
- Podcast co-host of “This Week in Virology” and “This Week in Parasitism”
- Co-author, *Parasitic Diseases*, 7th edition

Host

Leana McGuire, BS, RN

Leana McGuire has extensive experience with leadership development and executive coaching, and a background in content development, visual performance, speaking, and podcast hosting.

Content Reviewer

Maria Morales, MSN, RN, CLNC

Maria Morales is a nurse planner for Colibri Healthcare and a certified legal nurse consultant. She is a quality-focused, results-driven nursing education professional. As a continuing education leader with nurse executive experience in developing interprofessional educational programs, she supports healthcare workers with educational activities to help increase communication within the healthcare team.

References

- Butler, C. C., Yu, L. M., Dorward, J., Gbinigie, O., Hayward, G., Saville, B. R., Van Hecke, O., Berry, N., Detry, M. A., Saunders, C., Fitzgerald, M., Harris, V., Djukanovic, R., Gadola, S., Kirkpatrick, J., de Lusignan, S., Ogburn, E., Evans, P. H., Thomas, N. P. B., ... & PRINCIPLE Trial Collaborative Group. (2021). Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet: Respiratory Medicine*, 9(9), 1010–20. [https://doi.org/10.1016/S2213-2600\(21\)00310-6](https://doi.org/10.1016/S2213-2600(21)00310-6)
- Donnelly, C., Ashcroft, R., Bobbette, N., Mills, C., Mofina, A., Tran, T., Vader, K., Williams, A., Gill, S., & Miller, J. (2021). Interprofessional primary care during COVID-19: a survey of the provider perspective. *BMC Family Practice*, 22(1), 31. <https://doi.org/10.1186/s12875-020-01366-9>
- Hinks, T. S. C., Cureton, L., Knight, R., Wang, A., Cane, J. L., Barber, V. S., Black, J., Dutton, S. J., Melhorn, J., Jabeen, M., Moss, P., Garlapati, R., Baron, T., Johnson, G., Cattle, F., Clarke, D., Elkhodair, S., Underwood, J., Lasserson, D., ... & Richards, D. (2021). Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): An open-label, randomised trial. *Lancet: Respiratory Medicine*, 9(10), 1130–40. [https://doi.org/10.1016/S2213-2600\(21\)00263-0](https://doi.org/10.1016/S2213-2600(21)00263-0)
- Oldenburg, C. E., Pinsky, B. A., Brogdon, J., Chen, C., Ruder, K., Zhong, L., Nyatigo, F., Cook, C. A., Hinterwirth, A., Lebas, E., Redd, T., Porco, T. C., Lietman, T. M., Arnold, B. F., & Doan, T. (2021). Effect of oral azithromycin vs placebo on COVID-19 symptoms in outpatients with SARS-CoV-2 infection: A randomized clinical trial. *JAMA*, 326(6), 490–8. <https://doi.org/10.1001/jama.2021.11517>

PRINCIPLE Trial Collaborative Group. (2021). Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): A randomised, controlled, open-label, adaptive platform trial. *Lancet*, 397(10279), 1063–74. [https://doi.org/10.1016/S0140-6736\(21\)00461-X](https://doi.org/10.1016/S0140-6736(21)00461-X)